The optimal timing of initiation and duration of DAPT: recent findings and their impact on future patient care

This programme was a live accredited CME session in the past, no credits will be granted after May 20th 2015.

Chairpersons: R. MEHRAN, P. Gabriel STEG


To appreciate roles of DAPT in reducing ongoing cardiovascular disease risk and in-stent protection in patients with ACS
To review the recent clinical data exploring the optimal time of initiation and duration of DAPT in patients with coronary artery disease undergoing PCI
To explore how DAPT can be tailored to the patient to improve outcomes

Programme supported by an unrestricted educational grant from ASTRAZENECA.


Session objectives

P.G. Steg

What is the optimal time for DAPT initiation: P2Y12 inhibitor administration in the ambulance, emergency room or cathlab?

M. Möckel

What is the optimal DAPT duration for patients with coronary artery disease undergoing PCI?

M.P. Bonaca

Tailoring DAPT to the benefit: risk profile of the patient

M. Valgimigli

Session evaluation and key learnings

R. Mehran